ABSTRACT: Since the inception of the P50 Research Center in Injury and Peri-operative Sciences (RCIPS) funding mechanism, the National Institute of General Medical Sciences has supported a team approach to science. Many advances in critical care, particularly burns, have been driven by RCIPS teams. In fact, burns that were fatal in the early 1970s, prior to the inception of the P50 RCIPS program, are now routinely survived as a result of the P50-funded research. The advances in clinical care that led to the reduction in postburn death were made by optimizing resuscitation, incorporating early excision and grafting, bolstering acute care including support for inhalation injury, modulating the hypermetabolic response, augmenting the immune response, incorporating aerobic exercise, and developing antiscarring strategies. The work of the Burn RCIPS programs advanced our understanding of the pathophysiologic response to burn injury. As a result, the effects of a large burn on all organ systems have been studied, leading to the discovery of persistent dysfunction, elucidation of the underlying molecular mechanisms, and identification of potential therapeutic targets. Survival and subsequent patient satisfaction with quality of life have increased. In this review article, we describe the contributions of the Galveston P50 RCIPS that have changed postburn care and have considerably reduced postburn mortality. (J Trauma Acute Care Surg. 2017;83: 532-542.
M ultidisciplinary research teams have contributed to improving human health via innovative research approaches and discoveries since the early 1970s. The National Institute of General Medical Sciences (NIGMS) initiated the P50 Research Center in Injury and Peri-operative Sciences (RCIPS) funding mechanism to support research across the United States, funding 32 centers (Table 1) , each of which included scientifically related projects, core facilities, and a diverse workforce. Clinician and translational scientists operated in an environment that encouraged multidisciplinary collaboration and novel approaches to solving clinical problems; as investigators became leaders in the critical care arena, collaborative networks across the country were created. The impact of the RCIPS discoveries changed critical care significantly. Mortality following burns has decreased as a direct result of RCIPS funding, such that burns that were fatal prior to the inception of the RCIPS program are now routinely survived ( Table 2) . As a result, with burn patients surviving larger burns, establishment of therapies to improve the performance of routine daily activities and quality of life has become a priority. Here we highlight some of the Galveston P50 contributions toward burn care advancement. A list of more than 1,000 references from all Burn RCIPS, including additional publications from Galveston's RCIPS, is available upon request.
Burn Survival
Survival of a burn injury was once rare, with burns covering 20% of the total body surface area (TBSA) survived only half of the time ( Table 2 ). The advances in our understanding of the cellular mechanisms underlying burn injury have improved the standard of care and increased survival following burn injury ( Table 2) . [1] [2] [3] Now, a burn covering 90% of TBSA can be survived half of the time, as opposed to 60% of TBSA in the same age group prior to 1970 and the inception of the RCIPS. 1 The advances in burn treatment that have contributed to the reduction in morbidity and mortality include improved resuscitation, early excision and grafting, treatment of inhalation injury, optimized nutrition, modulation of hypermetabolism, better anti-infection treatments, improved psychosocial support, rehabilitation, and antiscarring treatments, each of which are detailed here (Table 3) .
Resuscitation
With appropriate resuscitation, survival from burn shock became routine. Optimization of resuscitation protocols revealed the importance of rapid initiation, the complications induced by delayed resuscitation, the perils of overresuscitation and underresuscitation, the benefits of guided fluid administration, utility of enteral resuscitation (especially for mass disaster scenarios), and considerations for special populations (e.g., pediatrics, pregnancy). 2, [4] [5] [6] [7] [8] Characterization of the hyperdynamic phase occurring 2 days to 3 days postburn showed low systemic vascular resistance, elevated cardiac output, systolic dysfunction, and increased myocardial energy demand. 5, 9 Heart rate and energy expenditure remain elevated for up to 3 years postburn, suggesting that interventions to correct prolonged cardiac dysfunction are needed. 10 Timely assessment of intravascular volume status and urinary output guides optimal intravascular volume, osmolality, electrolyte composition, oxygen delivery, tissue perfusion, and colloid osmotic pressure in order to prevent and mitigate organ failure. 1, [4] [5] [6] 11 Once hemorrhage and hypovolemia could be survived, sepsis became the focus. An increase in bacterial translocation and circulating endotoxin was attributed to decreased gastrointestinal mucosal blood flow. In the endotoxemic phase, treatment with either the vasodilator prostacyclin or angiotensin receptor blockade normalized mesenteric blood flow, oxygen delivery/consumption, and intrahepatic venous resistance. 11 Additional trials testing the efficacy and safety of therapies such as antithrombin III and peroxynitrite inhibitors, which have been tested in large animal models, are warranted.
Early Excision and Grafting of the Burn Wound
Building on Janzekovitch's establishment of early excision and grafting of the burn wound, research by RCIPS investigators established this as the standard of care. Delayed admission pushed back the timing of excision/grafting, leading to more invasive wound infections, greater incidence of sepsis, elevated inflammation, and longer hospital stays. [12] [13] [14] Our studies validated the safety and superiority of early excision compared with delayed. [12] [13] [14] Despite decreased mortality due to early excision and grafting, the inability to cover large burn wounds resulting from a lack of sufficient donor sites presented a significant clinical challenge. Deep partial-thickness wounds requiring 3 weeks or longer to heal will likely leave hypertrophic scars and disfiguring contractures. 15 For large burns, allograft is applied to burned regions until sufficient donor-site grafts can be harvested or cultured epidermal autografts created. 16 Graft materials are often meshed to expand the coverage material and are superior to cultured epidermal autografts when considering length of stay and the need for reconstruction surgeries. 16 Amnion can be used to cover partial-thickness facial burns without exacerbating scarring. 17 Grafts often result in scars that lack elasticity and flexibility. 15 Studies have focused on ways to increase graft take, and using the porcine model of excision and grafting, the slow-clotting fibrin sealant improved graft adherence following full-thickness burn. 18 Other strategies were used to develop artificial skin substitutes to rapidly cover large wounds; Integra, the first synthetic human skin used to cover large burn wounds, was developed with RCIPS funding awarded to Boston's John F. Burke. Galveston investigators showed that in children Integra use increased bone mineral content and density while reducing resting energy expenditure and hypertrophic scarring. 19 Additional approaches for faster burn wound healing are being explored, including human trials to confirm our 
Inhalation Injury
Improved resuscitation permitted the survival of previously fatal burns, unmasking the role of pulmonary insufficiency in postburn mortality 3 and persistence of pulmonary dysfunction for up to 8 years postburn. Several preclinical models were developed in Galveston to study the acute and long-term effects of an inhalation injury. 21, 22 The criterion standard preclinical model is an instrumented ovine survival model of severe smoke inhalation injury with positive pressure ventilation at 72 hours postexposure. 21 Modifications of this model to study burn with inhalation injury allowed testing of therapies, 22 such as nebulized heparin or N-acetyl cysteine, which significantly reduced mortality and reintubation rates in children with burns. The safety of nebulized epinephrine, shown to reduce lung lymph flow and protein content in the ovine model of burn and smoke inhalation injury, has now been demonstrated in a small cohort of pediatric burned subjects, paving the way for larger clinical trials. 23 Following studies of tidal volume in the ovine model, comparison of high and low tidal volume (15 ± 3 mL/kg vs. 9 ± 3 mL/kg) in pediatric burn patients with inhalation injury 24 showed significant reductions in days on a ventilator and incidence of atelectasis and acute respiratory distress syndrome with high tidal volume, establishing rationale for a larger prospective study.
The Metabolic Stress Response to Severe Burn Trauma Increased resting energy expenditure (i.e., hypermetabolism) is a hallmark of the stress response to severe burns, 24 and metabolic dysregulation can last for months or years. Hypermetabolism complicates the task of providing burn survivors with adequate nutrition, thereby contributing to long-term morbidity. Caloric supplementation is beneficial when energy expenditure needs are met. 26 Underfeeding the hypermetabolic patient exacerbates lean body mass catabolism, whereas overfeeding does not reverse the catabolism, but rather leads to accrual of fat mass. 26 the extent of injury and implicating catecholamines as novel mediators of the hypermetabolic response to burns. These early observations spawned decades of research into therapeutic strategies to blunt burn-induced hypermetabolism. The observation that conductive and evaporative heat loss from burn wounds contributed to hypermetabolism led to the development of environmental and wound management approaches that remain standards of care today. Preliminary evidence suggesting that β-adrenergic receptor (β-AR) blockade may be effective in reducing metabolic rate in burn victims has been confirmed by translational studies within our RCIPS. 29 The nonselective β-AR antagonist propranolol effectively mitigated the hypermetabolic response to burns. [29] [30] [31] Increased ATP turnover underlies approximately 55% to 60% of the hypermetabolic stress response to burns, meaning that oxygen consumption is outpacing ATP production at the level of the mitochondrion. Studies to define the role of mitochondria in the postburn hypermetabolic response have shown that mitochondrial respiration becomes uncoupled from ATP production in skeletal muscle 32 and white adipose tissue from burned patients. 33 In other words, mitochondria produce more heat in response to burns. These new data provide novel insight into the biochemical basis of the hypermetabolic stress response to burns and suggest that the mitochondrion may be a future target for strategies aimed at modulating this response.
Substrate metabolism is also profoundly altered by severe burn injury. The adrenergic stress response to burns that mediates hypermetabolism also increases circulating glycerol and fatty acids from lipolysis. 34 While glycerol may serve as a gluconeogenic precursor, the chronic oversupply of fatty acids into the systemic circulation contributes to hepatic steatosis. 27 The role of adrenergic stress and β 2 -AR agonism in mediating hyperlipolysis was confirmed, while providing evidence that the nonselective β-blocker propranolol may effectively remedy this issue.
In addition to altered lipid metabolism, glucose homeostasis is perturbed after burn, 35 as patients acutely exhibit a phenomenon termed stress-induced diabetes and may exhibit impaired glucose tolerance and hyperinsulinemia for months to years postburn. 36, 37 Loss of central (hepatic) insulin sensitivity has been implicated as the principal contributor to poor glucose control post injury, as basal glucose release from the liver is elevated with obligatory gluconeogenesis due to increased Cori and Cahill cycle fluxes. In addition to a loss of central insulin sensitivity, the capacity for insulin stimulated glucose disposal in peripheral tissue, namely, skeletal muscle, may also be diminished following severe burns. Whether this detriment in insulin sensitivity at the level of skeletal muscle is brought about by burn injury alone or through aftereffects following burn injury including infection, muscle catabolism, or enforced immobilization is difficult to delineate. Adherence to an intensive insulin protocol to maintain tight glycemic control can ameliorate this insulin resistance; however, the risk of hypoglycemia has prompted the investigation of other glucose-controlling strategies. 36, 38 Fenofibrate and metformin may be useful strategies to restore central and peripheral insulin sensitivity in children with severe burns. 39, 40 Decreased total body fat and subcutaneous peripheral fat, in concert with prolonged systemic inflammation, may drive persistent insulin resistance and predispose burn patients to subsequent cardiovascular disease and diabetes mellitus type 2. 41 Interestingly, mild obesity confers a survival benefit to burned adults, but not to children, whereas morbid obesity is associated with the highest mortality. 42 Altered protein metabolism is well documented in patients with massive burns and injuries. 43 Herndon, Wolfe and colleagues utilized stable isotopes to trace protein metabolism in burn patients in vivo. 25 These studies have contributed hugely to the understanding of burn-induced muscle catabolism and have aided in the development of therapeutic strategies for restoration of muscle mass and function following burn. Through an arterial-venous balance approach and infusion of stable isotopes of the amino acids phenylalanine, leucine, lysine, and valine, Biolo demonstrated that proteolysis was the principal mediator of altered skeletal muscle proteins turnover in burned adults. 44 Subsequent work has underscored this finding, demonstrating that elevated muscle protein turnover persists for up to 1 year postburn. 43 Furthermore, using five-pool modeling of amino acid kinetics in the arterial and venous blood, skeletal muscle, wound, and healthy skin, Gore and colleagues demonstrated that the marked efflux of amino acids from skeletal muscle into the blood was paralleled by a huge deposition of amino acids in burn wounds, suggesting that muscle proteolysis may support wound healing in burn patients.
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Modulating the Hypermetabolic Response
The overarching goal of the Galveston P50 has been to modulate the postburn hypermetabolic response with a number of pharmacologic strategies to blunt muscle protein wasting, increase muscle anabolism, or decrease hyperglycemia, ultimately promoting the long-term restoration of muscle mass and function. 25, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] One such agent, propranolol, is a nonselective β-AR antagonist that attenuates the actions of catecholamines and limits hypermetabolism and hypercatabolism after burn 29, 57 and stimulates muscle protein accretion. 29 In burned patients, propranolol reduced tachycardia 29, 57, 58 and the percent predicted heart rate, 29 attenuated resting energy expenditure, 29, 57, 59 and decreased cardiac work, stress, and output. 60 Propranolol also reduces cardiac stress by decreasing cardiac index in burn patients without adversely affecting peripheral perfusion. 61 Improvements in body composition were also seen following propranolol administration, with resultant improvements in lean body mass, 29 decreased accumulation of central fat, 29 and reduced bone loss. 29 With propranolol administration, blood loss was reduced during skin grafting procedures, and the number of days between procedures was fewer, indicating improved donor-site wound healing in propranolol-treated patients. 58 Mechanistic studies in the rabbit showed that propranolol increases wound healing by inducing the synthetic rate of wound protein. 62 Systemic inflammation was also attenuated, with decrements in circulating concentrations of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) . 59 Murine models suggest that the use of propranolol may lead to increased risk of mortality in septic patients, although studies of propranolol in human burn patients showed no increased risk of infections, sepsis, or mortality. 59 Oxandrolone is a synthetic dihydrotestosterone derivative that, in the severely burned, decreases length of stay, 63 Finnerty et al.
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improves lean body mass and muscle accretion, 48, 63 increases bone mineral content and bone mineral density, 49 enhances wound healing, accelerates growth rate, 50 decreases the risk of osteoporosis, 50 reduces protein breakdown, 64 improves muscle strength, 48 and improves lung function. 52 Burned adults receiving oxandrolone within 7 days of injury have decreased mortality compared with untreated controls. 65 In the pediatric population, oxandrolone is less virilizing than testosterone, has minimal hepatotoxicity, and is nonaromatizable, preventing conversion to estrogen and estrogen-dependent early growth plate closure in long bones. 50 The benefits of oxandrolone administration persist for several years after the drug is no longer being given, 47, 50, 66 and administration for 2 years postburn may yield even greater improvements. 50 Administration of recombinant human growth hormone (rhGH) decreased catabolism alongside increased protein synthesis, resulting in both muscle and bone growth. Patients in the rhGH cohort also experienced decreased length of stay, fewer reconstructive surgeries, and improved skin-graft donor-site healing. Body composition changes attributed to rhGH included an increase in lean body mass in addition to the rhGH-treated patients attaining greater height and weight. 67 Decreases in acute-phase proteins, TNF-α, and IL-1β, alongside increases in insulinlike growth factor 1 (IGF-1) and constitutive hepatic proteins, were reported with rhGH administration. 68 The effects of growth hormone are mediated via the stimulation of IGF-1 and its binding protein, IGFBP-3. In pediatric burn patients, the administration of both IGF-1 and IGFBP-3 resulted in improved protein metabolism without hypoglycemia, one of the adverse effects of the administration of rhGH. This combination also attenuated Types I and II hepatic acute-phase responses, increased levels of constitutive serum protein levels, and decreased postburn muscle catabolism. 69 Insulin administration improves clinical outcomes such as bone mineral content and muscle strength in patients with severe burns. 36 The use of insulin as an antihyperglycemia therapy in this population resulted in improved donor-site healing, increased muscle protein synthesis, and decreased lean body mass loss and acute-phase responses. 70, 71 When blood glucose concentrations were reduced to 130 mg/dL, significant reductions in the incidence of infections, sepsis, and mortality occurred in addition to the attenuation of the postburn hypermetabolic and inflammatory responses. 70 The increased incidence of hypoglycemia with insulin administration and an increase in mortality, 36, 70 however, led to the evaluation of other antihyperglycemic strategies, including metformin and fenofibrate. Metformin, a biguanide drug, has been used to control postburn hyperglycemia without the increased risk of hypoglycemic episodes. 70, 72 A randomized study showed that metformin improves glucose control by decreasing endogenous production of glucose and by increasing peripheral glucose clearance and oxidation. 40, 72 In burned patients, muscle protein fractional synthetic rate increased with metformin administration, and net protein balance improved. 40 Acute administration of fenofibrate increased insulin sensitivity and insulin receptor signaling, with decreased plasma glucose concentrations and increased mitochondrial ATP production. 39 The role of hypercortisolemia in the postburn response was examined via administration of the cortisol synthesis inhibitor ketoconazole. 73 Although cortisol production was significantly reduced, ketoconazole did not affect the catabolic, inflammatory, or hypermetabolic responses, indicating that high levels of cortisol may not contribute significantly toward the postburn hypermetabolic response.
Combinations of the drugs described previously were also trialed to determine whether the combination could be more efficacious than the individual therapies. In order to test the hypothesis that coadministration of propranolol and rhGH would synergistically reduce hypermetabolism and catabolism to markedly improve patient outcomes, a small pilot study was performed. The significant reduction of heart rate and rate of free fatty acid release supported this hypothesis. However, later studies in larger cohorts did not confirm the benefits of combined propranolol and rhGH therapy. 57, 68 Similarly, the combination of propranolol with rhGH did not improve anabolism over the effect achieved with propranolol alone; 57 however, peripheral lipolysis and inflammation, two adverse effects attributed to the administration of rhGH, were significantly reduced with the coadministration of propranolol. 68 Although propranolol did diminish the adverse effects induced by rhGH, synergy in the mechanisms of action was not found.
The combination of propranolol with oxandrolone has demonstrated synergism; the postburn growth arrest was attenuated, and the subsequent growth rate significantly improved with the combined administration of oxandrolone and propranolol. 66 Further studies of the effects of propranolol in combination with oxandrolone are needed to determine how adults are affected, the effects on hypertrophic scarring, and other tissue-specific responses and to determine the sex dependence of outcomes following the administration of this androgen to female and male burn patients.
Infection, Inflammation, and Altered Immunity
Infection and sepsis are now the leading causes of death following burn injury and substantially influence morbidity in surviving patients. Within minutes of a major burn injury, profound immune alterations occur, rendering the host unable to generate novel cell-mediated immune responses. The host is left dependent on innate immunity and existing responses, with increased mortality observed when these remaining mechanisms are defective or rendered inactive. 74 Accordingly, stimulation of the remaining functional immune mechanisms has been investigated in response to viruses, bacteria, and fungi that are problematic for burned patients. [74] [75] [76] [77] Burn-induced immune alterations also include decreased natural killer cell activity 74, 75 and the formation of immunologically anergic M2b monocytes in peripheral blood. 78, 79 The formation of these anergic monocytes is induced by catecholamines, but can be blocked by propranolol administration in children with burns. 80 Burn also impairs the antigen-specific adaptive system. Burn-associated T cells (BA2T cells, CD8 + T cell receptor α/β) during healing and can be countered by IL-12. Greater understanding of postburn alterations in host immunity will allow improvements in burn care and survival. To this end, the genomic response to burn in white blood cells involves the majority of the genome with enduring perturbations. 81 The unique differences in the genomic response to burns in mice and humans 82 emphasize the importance of conducting experiments in animal models, such as our humanized mouse model, 75 or in cells obtained from patients. 78, 79 The past decade of biomarker research has resulted in the elucidation of characteristic postburn protein expression profiles. Systemic release of large quantities of proinflammatory and anti-inflammatory proteins affects organ function, immune function, and the hypermetabolic and hypercatabolic responses. [83] [84] [85] [86] [87] Understanding the postburn release of inflammatory mediators may be essential to predict untoward outcomes and provide treatment personalized to optimize outcomes. [83] [84] [85] [86] [87] Sixteen cytokines are elevated immediately following burn injury, 85, 88 with some perturbations persisting. 89 The most favorable window for intervention appears to be during the first postburn week when release of inflammatory proteins is the greatest. 85, 88 Plasma protein expression and the accompanying hypermetabolic response vary with sex, 90 presenting a potential barometer for monitoring efficacy of various interventions. Early elevation of cytokine expression was indicative of future sepsis development, with elevated IL-6 and IL-12 p70 and lower TNF indicating an elevated risk of death by sepsis. 83 Additional work demonstrated an association between IL-8 concentrations and infection risk. 91 Similar studies confirmed the predictive potential of cytokine expression for inhalation trauma 84 and survival. 86, 87 We have not yet determined how best to modulate this pathophysiologic response to improve outcomes, although agents such as propranolol, oxandrolone, insulin, and recombinant growth hormone impact cytokine release. 29, 47, 59, 63, 68, 70 Additional plasma proteins modulated by burn injury may be predictive of death. 86 Similarly, triglyceride elevation was associated with poor postburn outcomes, including increased inflammation and hypermetabolism. 34 C-reactive protein, a marker of postburn inflammation, is not an adequate marker for infection and sepsis in the severely burned patient. The accuracy of prediction of patient outcome based on clinical characteristics such as burn size, presence of inhalation injury, and patient age can be improved upon by incorporating expression of a panel of biomarkers, including acute-phase proteins, cytokines, and clinical chemistries, into the predictive models.
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Postburn Exercise
The importance of strengthening the patient's physical condition became a crucial aspect of recovery upon realization of the reduction of daily activities in burn survivors. 92 The first exercise program improved strength and muscle function and demonstrated that a structured exercise program during the rehabilitative stage led to beneficial results in the severely burned. 55 The program included moderate intensity, progressive resistance, and aerobic exercises and was conducted three times a week for 12 weeks. 55 The 12-week in-hospital exercise program led to improvements in cardiopulmonary and muscle function, which were still lower in burned survivors randomized to exercise than in a noncontrol group, but significantly higher in relation to the nonexercise group of children with burns. 54 Recent work suggests that despite activation of the satellite cells, the stem cells responsible for skeletal muscle regeneration, by burn injury a concurrent increase in apoptosis of these cells results in a net loss of the cells needed to regenerate lean muscle tissue. 46 The combination of exercise programs with other approaches for improving physical outcome was also tested. Patients receiving growth hormone and enrolled in an exercise program had greater muscle strength following the conclusion of a 12-week exercise program. 56 However, this study also showed that exercise in the burn patient had to be studied further as body temperature elevations may not be compensated for correctly in these patients. 93 One of the next studies established practice guidelines for safely exercising, controlled exercise programs with moderately intense exercises for not more than 20 minutes, in an environment kept at room temperature (22°C), in patients with less than 75% of TBSA burned. 93 The benefits of participating in an exercise program persisted beyond the period while the patient was actively participating; 3 months after discharge, lean body mass and muscle strength remained significantly higher than in the nonexercise control group. 53 This benefit is lost by 2 years postburn, suggesting that continuing exercise maintenance programs after discharge would benefit children with severe burns even more. 94 Additional studies in children younger than 7 years demonstrated that the addition of music or oxandrolone to the exercise regimen synergistically improved outcomes. 48, 95 Exercise programs, in conjunction with general wellness programs, also improve psychological outcomes. 51 Exercise was initially started 6 months to 9 months postburn, transitioned to immediately postdischarge, and is being studied for even earlier implementation.
Despite the myriad benefits of exercise training to patients with severe burns, exercise programs are not the standard of care at most institutions. Because of the utility of exercise in restoring function in burn survivors, we advocate the incorporation of structured exercise programs into the outpatient care following discharge from the acute unit. Indeed, early outpatient exercise training implemented at the time of hospital discharge represents an additional intervention for the improvement of muscle mass and function after severe burn injury. 94 Furthermore, alternative rehabilitation achieved via community-based training programs conducted in centers close to the patient's home enables improvements in body lean mass, strength, and cardiopulmonary capacity. 96 
Postburn Hypertrophic Scarring
Quality of life in burn survivors may be compromised because of the physical appearance of scar, reduced function of scarred joints, or persistent itch and pain emanating from scars. 97 Lessening the impact of the extensive scarring that affects 70% to 90% of patients with severe burns has become a research priority, prompting the development of reliable animal models to study postburn wound healing and hypertrophic scarring 15, 18, 98, 99 to parallel studies of the patients themselves. Various strategies have been trialed to reduce postburn scarring in the clinic. [15] [16] [17] 19 Burn patients who develop hypertrophic scarring frequently have delayed wound healing due to chronic inflammation or infection. 15 One of the most effective methods for reducing inflammation in the burn wound, early excision and grafting, also reduces hypertrophic scarring. [12] [13] [14] Splints were widely used in the past to minimize scar contraction and hypertrophy. 100 Pressure garments have also been efficacious Finnerty et al. for reducing scarring but should be worn for up to 2 years postburn or until the scar matures. 15 Additional effective therapies for reducing the already formed postburn hypertrophic scar include surgical release, laser therapy, or subcicatricial and intracicatricial fat injection. 15 Scar severity can be assessed with photographic planimetry and evaluated using various scar scoring scales. 101, 102 A scale for assessing photographs of postburn scarring was validated in children with severe burns. 102 Assessment of scar color and pigmentation is possible with the derma-spectrometer and chromometer, whereas the pneumatonometer and durometer measure scar pliability, and scar vascularity and perfusion can be estimated with laser Doppler ultrasound. 101 These methods were used to compare the effects of administration of rhGH 0.05 mg/kg per day for 1 year with placebo on hypertrophic scarring. 103 Although scar severity was similar in both groups, donor-site healing time decreased significantly in GH-treated patients. 103 Patients receiving rhGH underwent significantly fewer reconstructive surgeries, indicating a reduction in function-impairing scar contractures in the rhGH-treated patients. Significant reduction of scarring was achieved with rhGH 0.1 mg/kg and 0.2 mg/kg per day. 67 This decrease in scarring is attributed to increased patient activity and use of affected joints during the scar maturation phase in rhGH-treated patients.
Chronic increases in catecholamine concentrations following burn injury may be the main culprit underlying increased postburn hypermetabolism, elevated inflammation, and hypertrophic scarring. Catecholamines act on cell proliferation and extracellular matrix remodeling mainly through the b-AR receptors. Studies have demonstrated that wound protein synthesis can be bolstered with propranolol treatment; 62 use of propranolol decreases the average number of days between skin grafting procedures, which suggests faster donor-site wound healing in patients randomized to propranolol. 58 Studies into the effect of propranolol on hypertrophic scarring are continuing.
To understand the molecular mechanisms underlying postburn hypertrophic scarring, dermal fibroblasts from hypertrophic scars and nonburned skin from burned patients have been used to elucidate the roles of various signaling pathways in the fibrotic response. 15, 104, 105 The roles of IL-6 transsignaling STAT3, BRD4, and CDC9 in mediating extracellular matrix production and myofibroblast transdifferentiation in postburn scar recently have been elucidated. 105 The reduced sensitivity of fibroblasts from hypertrophic scar to IL-6 may effectively suppress extracellular matrix remodeling, leading to excessive collagen accumulation. Smad 2 and Smad ubiquitination regulatory factor 2, mediators of TGF-β activity, were also implicated in the progression of hypertrophic scarring. 104 Collagen Type III accumulation in postburn scars is greater than in nonhypertrophic scars for up to 24 months after injury. During this same time frame, collagen Type I protein expression does not change, suggesting that collagen Type III can be useful for differentiating between hypertrophic and nonhypertrophic scars 106 and may serve as an indicator of therapeutic efficacy.
CONCLUSIONS
The NIGMS investment in research infrastructure, including administrative and clinical research support, database curation, biospecimen repositories, and an established network of clinical research sites capable of performing complex clinical trials, enabled the success of the RCIPS programs. Specialized techniques developed through the projects and cores benefitted the larger research community, including stable isotope methodologies; microfluidics, proteomics, immunologic, and genomics technologies; and animal models of burn, infection, and inhalation injury. 5, 11, [17] [18] [19] 21, 24, 26, 27, 32, 33, 40, 75, 81, 82, 86, 95, 98, [100] [101] [102] 106 The Burn P50 RCIPs, along with the associated postdoctoral T32 training grants, P01 program project grants, and multi-institutional U54 grants funded by the NIGMS, and more recently, the Clinical and Translational Science Award from the National Center for Advancing Translational Sciences, have expanded our understanding of burn pathophysiology and importantly have improved the care of the severely burned (Table 3) , reducing morbidity and mortality in the severely burned. The lifesaving advancements would not have occurred in such a short period without P50 RCIPS funding and the creation of research centers that became the foci of burn and critical illness research and care. Other acute care surgery fields could benefit from similar focused funding for team science to support major advancements in patient outcomes. 
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